In the preceding three months, 18 analysts have released ratings for CME Gr (NASDAQ:CME), presenting a wide array of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $234.0, a high estimate of $258.00, and a low estimate of $180.00. This upward trend is apparent, with the current average reflecting a 4.28% increase from the previous average price target of $224.40.

Understanding Analyst Ratings: A Comprehensive Breakdown

The analysis of recent analyst actions sheds light on the perception of CME Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CME Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on CME Gr analyst ratings.

Discovering CME Gr: A Closer Look

CME Gr's Economic Impact: An Analysis

Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.

Revenue Growth: CME Gr's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 18.43%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.

Net Margin: CME Gr's net margin is impressive, surpassing industry averages. With a net margin of 56.89%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): CME Gr's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.23%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): CME Gr's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.69%, the company may face hurdles in achieving optimal financial returns.

Debt Management: CME Gr's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.